- Proteins and Peptides
- Lysates and Cell Lines
Antibodies against 69 C. elegans chromosomal proteins generated by the modENCODE project are now commercially available through Novus Biologicals, SDIX™ pre-made antibody distributor. The modENCODE project (model organism ENCyclopedia Of DNA Elements) is funded by the NIH to identify all of the DNA sequence-based functional elements in the Caenorhabditis elegans (C. elegans) and Drosophila melanogaster genomes.
The modENCODE antibodies available through Novus come from a group headed by Dr. Jason Lieb (University of North Carolina, Chapel Hill) that is focused on chromosome-associated proteins in C. elegans. C. elegans is a free-living nematode about 1 mm in length. It is a key model organism that has been used for decades by thousands of researchers. Research advantages include its small size, short life cycle, optical transparency, and the many genes and pathways that it shares with humans and that are common to all animals. C. elegans antibodies are often difficult to find commercially, therefore the partnership between modENCODE, SDIX and Novus is a significant step forward.
The modENCODE project recently published a paper in Science outlining their work improving the annotation of the C. elegans genome (Gerstein MB, et al. PMID: 21177976). This characterization includes transcriptome profiling across a developmental time course, genome-wide identification of transcription factor-binding sites, and maps of chromatin organization. Additional work on C. elegans, as well as Drosophila, will be continued and can be viewed on the modENCODE Blog.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
About SDIX (www.sdix.com)
SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the pharmaceutical, biotechnology, diagnostics, and food safety markets. For 20 years, SDIX has developed antibodies which advance its customer™ immuno-based work reducing time, labor, and costs while increasing accuracy and reliability of results.
SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development, and production. In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide tools for rapid diagnosis.
The antibodies were developed using SDIX™s proprietary Genomic Antibody Technology (GAT). This technology allows the antibodies to be designed to conform to the native structure of the protein, resulting in a more specific and sensitive antibody that has a higher success rate in various assays and applications. The affinity-purified rabbit polyclonal antibodies have been validated for use in one or more of several of applications, including chromatin
This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like anticipate,could, enable,estimate, intend, expect, believe, potential, will, should, project, plan and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.